Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
The study linked and excerpted below cites a small study of MGUS patients, 70% of whom had the HPV virus reside in their bone marrow.
Have you been diagnosed with this form of pre-myeloma? Please scroll down the page, post a question or a comment and I will reply to you ASAP.
MGUS at a glance- click the illustration below:
Let me be clear. According to my research there is no evidence that HPV causes MGUS or the other way around. I am writing about MGUS and HPV because I am a long-term survivor of multiple myeloma and I had HPV at one time. I say “had” HPV for two reasons. First, this HPV virus is known to resolve on it’s own. Secondly I supplemented with AHCC (see below) to make sure that the HPV virus resolved.
Based on my experience and research I believe that all stages of pre-multiple myeloma- a single plasmacytoma, MGUS and SMM can all be managed in an effort to prevent a full-blown multiple myeloma diagnosis. In addition, it is clear that HPV can be resolved as well.
To learn more about the evidence-based protocols you can follow to prevent your Pre-Myeloma from becoming Multiple Myeloma, please watch the short video below:
If you do not want to “watch and wait” to see if your MGUS progresses to Multiple Myeloma scroll down the page, post a question or a comment and I will reply to you ASAP.
Consider MGUS Therapies such as:
“In the following study, we expanded upon our initial observation by analyzing 14 patients with MGUS…
Among 14 patients with MGUS, HPV sequences have been identified in 10 of the bone marrow biopsies. These results suggest that HPV can reside in the bone marrow of a premalignant lymphoproliferative disease.”
“A recent study looked at AHCC as a potential natural treatment for HPV (human papillomavirus). It examined the immune support supplement’s effect on two specific strains of the virus; the researchers concluded that daily dosing of AHCC successfully eradicated the expression of these strains in mice and may have a role in the prevention of HPV-related cancer…”
“Objective: There is currently no effective medicine or supplement for clearance of high risk- human papillomavirus (HR-HPV) infections. We have taken a systematic approach evaluating the potential use of AHCC supplementation to support clearance of HR-HPV infections. The primary objective of this research was to evaluate AHCC supplementation to modulation of the host immune system to clear HR-HPV infections from bench to bedside.
Methods: Cervical cancer cells, CaSki (HPV16+), HeLa(HPV18+), SiHa(HPV16/18+), and C-33A(HPV−), were treated in vitro with AHCC 0.42 mg/mL daily x7 days then observed x7 days with daily sample collection. A confirmatory study in cervical cancer mouse models, SiHa(HPV16/18+) and C-33A(HPV−), was conducted: mice were divided into three groups per cell line then dosed with AHCC 50 mg/kg/d (N = 10), or vehicle alone (N = 10), or no supplementation (N = 10) for a total of 90 days followed by 30 days of observation. Tumors were measured 3x/week and blood samples collected bi-weekly to evaluate interferon (IFN) alpha(α), beta(β), and gamma(γ) and immunoglobulin G(IgG) by immunoassays. Tumors were evaluated for HR-HPV expression by PCR. Two pilot studies of 10 patients each were conducted in women with confirmed persistent HR-HPV+ infections. The 1st study evaluated AHCC 3g from 5 weeks up to 6 months and 2nd study evaluated AHCC 1g < 8 months. HR-HPV DNA status and the immune panel were monitored at each visit.
Results: HR–HPV clearance was observed in vitro and confirmed in the animal studies as a durable response. Four of six (66.7%) patients had confirmed HR-HPV clearance after 3–6 months of AHCC 3g. Similarly, 4 of 9 (44%) patients had confirmed HR-HPV clearance after 7 months of AHCC 1g. Suppression of IFNβ <25 pg/mL was observed in those clearing the HR-HPV infection.
Conclusion: Pre-clinical in vitro and in vivo studies demonstrated durable clearance of HR-HPV infections. The preliminary data from the two pilot studies suggested that AHCC supplementation supports the host immune system for successful clearance of HR-HPV infections. A confirmatory phase II randomized, double-blinded, placebo-controlled study is ongoing.